BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1564 related articles for article (PubMed ID: 27086085)

  • 1. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
    Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Sartori C; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Platelets; 2016 Sep; 27(6):576-82. PubMed ID: 27540959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
    Verdoia M; Nardin M; Sartori C; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Atherosclerosis; 2015 Dec; 243(2):389-94. PubMed ID: 26520891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
    Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Schaffer A; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G
    J Thromb Haemost; 2016 Jan; 14(1):57-64. PubMed ID: 26512550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; Luca GD;
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):143-50. PubMed ID: 26868495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Drugs Ther; 2015; 29(5):443-50. PubMed ID: 26428927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
    Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G
    J Thromb Thrombolysis; 2016 Aug; 42(2):245-53. PubMed ID: 26951167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
    Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Rolla R; Pergolini P; Gioscia R; Nardin M; Negro F; Viglione F; Suryapranata H; Kedhi E; De Luca G;
    Catheter Cardiovasc Interv; 2021 Dec; 98(7):1309-1316. PubMed ID: 33527669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.
    Verdoia M; Sartori C; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Feb; 77():48-53. PubMed ID: 25956733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
    Verdoia M; Rolla R; Negro F; Tonon F; Pergolini P; Nardin M; Marcolongo M; De Luca G;
    Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):292-299. PubMed ID: 31780401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Tonon F; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    J Thromb Thrombolysis; 2019 Oct; 48(3):413-421. PubMed ID: 31065927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.